The OJC 51: Prostate Cancer Screening, ASCO IO Guidelines and Infigratinib

Pinterest LinkedIn Tumblr +

The Oncology Journal Club Episode 51: Prostate Cancer Screening, ASCO Guidelines and Infigratinib

Welcome to this week’s episode of The OJC. Join Eva Segelov, Craig Underhill and Hans Prenen as they review an eclectic mix of papers covering prostate cancer screening, ASCO guidelines for immunotherapy for locally advanced esophageal carcinoma, infigratinib in advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements, Quick Bites, Zoom Fatigue and much more.

We hope you enjoy the Amazing Article of the Week, the Practice Tip of the Week and have a few laughs too.

Drop us a line on Twitter with any comments @oncologynewsaus

This Week’s Papers:

  1. Eklund M, et al. MRI-Targeted or Standard Biopsy in Prostate Cancer Screening. N Engl J Med. 2021 Sep 2;385(10):908-920. doi: 10.1056/NEJMoa2100852. Epub 2021 Jul 9. PMID: 34237810. Access online here.
  2. Shah MA, et al. Locally Advanced Esophageal Carcinoma Guideline Expert Panel. Immunotherapy in Patients With Locally Advanced Esophageal Carcinoma: ASCO Treatment of Locally Advanced Esophageal Carcinoma Guideline Rapid Recommendation Update. J Clin Oncol. 2021 Oct 1;39(28):3182-3184. doi: 10.1200/JCO.21.01831. Epub 2021 Aug 18. PMID: 34406872. Access online here.
  3. Javle M, et al. Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study. Lancet Gastroenterol Hepatol. 2021 Oct;6(10):803-815. doi: 10.1016/S2468-1253(21)00196-5. Epub 2021 Aug 3. PMID: 34358484. Access online here.

This Week’s Quick Bites:

  1. Rose TL, et al. Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. J Clin Oncol. 2021 Oct 1;39(28):3140-3148. doi: 10.1200/JCO.21.01003. Epub 2021 Aug 24. PMID: 34428076; PMCID: PMC8478388. Access online here.
  2. Masarwy R, et al. Neoadjuvant PD-1/PD-L1 Inhibitors for Resectable Head and Neck Cancer: A Systematic Review and Meta-analysis. JAMA Otolaryngol Head Neck Surg. 2021 Sep 2:e212191. doi: 10.1001/jamaoto.2021.2191. Epub ahead of print. PMID: 34473219; PMCID: PMC8414366. Access online here.
  3. Gyawali B, et al. Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study. BMJ. 2021 Sep 8;374:n1959. doi: 10.1136/bmj.n1959. PMID: 34497044; PMCID: PMC8424519. Access online here.
  4. Javle M, et al. Pertuzumab and trastuzumab for HER2-positive, metastatic biliary tract cancer (MyPathway): a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2021 Sep;22(9):1290-1300. doi: 10.1016/S1470-2045(21)00336-3. Epub 2021 Jul 30. PMID: 34339623. Access online here.
  5. Kang YK, et al. Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study. J Clin Oncol. 2021 Oct 1;39(28):3128-3139. doi: 10.1200/JCO.21.00217. Epub 2021 Aug 3. PMID: 34343033; PMCID: PMC8478403. Access online here.
  6. van de Haar J, et al. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure. Nat Med. 2021 Sep;27(9):1553-1563. doi: 10.1038/s41591-021-01448-w. Epub 2021 Aug 9. PMID: 34373653. Access online here.
  7. Chesney TR, et al. All-Cause and Cancer-Specific Death of Older Adults Following Surgery for Cancer. JAMA Surg. 2021 Jul 1;156(7):e211425. doi: 10.1001/jamasurg.2021.1425. Epub 2021 Jul 14. PMID: 33978695; PMCID: PMC8117065. Access online here.
  8. Hallet J, et al. Risk of Cancer-Specific Death for Patients Diagnosed With Neuroendocrine Tumors: A Population-Based Analysis. J Natl Compr Canc Netw. 2021 Jun 4:1-10. doi: 10.6004/jnccn.2020.7666. Epub ahead of print. PMID: 34087785. Access online here.
  9. Stiller A, et al. The Supportive Care Needs of Regional and Remote Cancer Caregivers. Curr Oncol. 2021 Aug 9;28(4):3041-3057. doi: 10.3390/curroncol28040266. PMID: 34436032; PMCID: PMC8395470. Access online here.
  10. van der Kruk SR, et al. Psychosocial well-being and supportive care needs of cancer patients and survivors living in rural or regional areas: a systematic review from 2010 to 2021. Support Care Cancer. 2021 Aug 14:1–44. doi: 10.1007/s00520-021-06440-1. Epub ahead of print. PMID: 34392413; PMCID: PMC8364415. Access online here.
  11. Butow PN, et al. Psychosocial well-being and supportive care needs of cancer patients living in urban and rural/regional areas: a systematic review. Support Care Cancer. 2012 Jan;20(1):1-22. doi: 10.1007/s00520-011-1270-1. Epub 2011 Sep 29. PMID: 21956760. Access online here.

Amazing Article of the Week:

Shockley KM, et al. The fatiguing effects of camera use in virtual meetings: A within-person field experiment. J Appl Psychol. 2021 Aug;106(8):1137-1155. doi: 10.1037/apl0000948. PMID: 34423999. Access online here.

Twitter Account of the Week:

Jessica Rodrigues @rodriguesjm6

Other Episodes Mentioned:

This Week’s Team:

Professor Eva Segelov

Eva Segelov

Professor Eva Segelov is a Medical Oncologist and is Director of Oncology at Monash University and Monash Health, Melbourne, Victoria, previously Senior Medical Oncologist at St Vincent’s Hospital, St Vincent’s Private Hospital and St Vincent’s Clinic and Associate Professor of Medicine, University of New South Wales.

Eva has an interest in academic clinical trials in GI and breast cancer and has been a member of the AGITG since 2003. She has clinical trials expertise, links with national and international trials groups, and extensive experience with adult medical education.

You can find Eva on Twitter here: @profevasegelov

Professor Hans Prenen

Hans Prenen

Professor Hans Prenen is a medical oncologist and head of the phase 1 – early clinical trials unit at the Antwerp University Hospital in Belgium. He is a member of several scientific organisations, published many scientific oncology papers in prestigious journals and is regularly invited for lectures at national and international meetings.  His interests are clinical trials and translational research with a focus on digestive oncology.

You can find Hans on Twitter here: @HPrenen

Dr Craig Underhill

Craig Underhill

Dr Craig Underhill completed his Bachelor of Medicine and Surgery in 1987 at Melbourne University. He completed medical oncology training in Melbourne and worked as the Senior Clinical Research Registrar at Guy’s Hospital, London.

In 1998 arrived in Albury-Wodonga and established a medical oncology practice and clinical trials unit which has developed expertise and infrastructure to ensure the initiation of high quality trials. The research Unit lead by Dr Underhill has twice been awarded NSW Premier’s Award for Innovation in Cancer Clinical Trials, the inaugural award in 2009 and then again in 2012.

Dr Underhill chaired a working party that was instrumental in securing $65 million in federal funding for The Albury Wodonga Regional Cancer Centre which opened in September 2016.

Dr Underhill is the VCCC Regional Oncology Lead and advocates for the increased access to clinical trials for regional Victorians and leads the VCCC teletrials program.

You can find Craig on Twitter here: @CraigUnderhill 

Rachael Babin

Rachael Babin is Editor-in-Chief of The Oncology Newsletter, Publisher of Oncology News Host of The Oncology Podcast and Producer of The Oncology Journal Club. For regular oncology updates for healthcare professionals, please subscribe to The Oncology Newsletter.

With thanks to Eva Segelov, Craig Underhill, Hans Prenen and Graham Knowles.

Connect with us on Twitter @OncologyNewsAus


About Author

The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.

Leave A Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.